沙库巴曲缬沙坦钠联合左西孟旦对瓣膜病心衰患者的临床疗效及心功能影响

Abstract
Figure/Table
References
Related Citation (11)

Download: PDF (2552 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical efficacy and cardiac function of nohintal (sacubactril valsartan sodium) combined with levosimendan in patients with valvular heart failure. Methods 150 patients with valvular heart failure admitted to our hospital from October 2019 to October 2022 were selected as research objects, and were divided into observation group and control group by random number table method, with 75 cases in each group. The control group was treated with levosimendan, and the observation group was treated with nocinol combined with levosimendan. After 3 courses of treatment, the clinical efficacy, cardiac function, vascular endothelial function, myocardial injury markers and therapeutic safety of the two groups were evaluated. Results 1 case of voluntary withdrawal in the observation group, 2 cases of adjustment of treatment plan, 2 cases of voluntary withdrawal in the control group, and 1 case of missing observation index results were excluded from this study. The total effective rate of observation group was 91.67% (66/72), which was higher than that of control group 77.78% (56/72) (P<0.05). After treatment, left ventricular ejection fraction (LVEF) and cardiac output (CO) in observation group were higher than those in control group, but left ventricular end-diastolic diameter (LVEDD) and left ventricular end-diastolic volume (LVEDV) in observation group were lower than those in control group. After treatment, the levels of angioendothelin-1(ET-1) and angiotensin-II (Ang-II) in observation group were lower than those in control group, and the levels of nitric oxide (NO) were higher than those in control group. After treatment, the levels of cardiac fatty acid-binding protein (H-FABP), myoglobin (MYO) and extracellular matrix metalloproteinase-inducing factor (EMMPRIN) in observation group were lower than those in control group. The incidence of adverse reactions in the two groups was 11.11% (8/72) and 8.33% (6/72), respectively, and there was no significant difference between the two groups. Conclusion Nohintal combined with levosimendan has significant clinical efficacy in patients with valvular heart failure, which can improve the cardiac function and vascular endothelial function, reduce the level of myocardial cell injury markers, and has good therapeutic safety.

Key words： valvular disease heart failure levosimendan sacubactril sodium valsartan heart function vascular endothelial function markers of myocardial injury

Received: 27 March 2024

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GAO Junjie
	LI Runjun
	ZHANG Lifang
	TANG Xiuying

Cite this article:

GAO Junjie,LI Runjun,ZHANG Lifang等. Clinical efficacy and cardiac function of Sacubactril sodium valsartan combined with levosimendan in patients with valvular heart failure[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2024, 21(4): 41-44.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2024/V21/I4/41

[1] VAHANIAN A, BEYERSDORF F, PRAZ F, et al.2021 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J, 2022, 43(7): 561-632.
[2] ALURU JS, BARSOUK A, SAGINALA K, et al.Valvular Heart Disease Epidemiology[J]. Med Sci (Basel), 2022, 15(2): 32-38.
[3] 陶涛, 刘毅龙. 重组人脑利钠肽联合沙库巴曲缬沙坦钠片治疗冠状动脉粥样硬化性心脏病心力衰竭疗效观察[J]. 新乡医学院学报, 2022, 39(3): 258-263.
[4] COFFEY S, ROBERTS-THOMSON R, BROWN A, et al.Global epidemiology of valvular heart disease[J]. Nat Rev Cardiol, 2021, 18(12): 853-864.
[5] 韦柳炎, 焦国庆, 李明秋. 双房双极及单房单极射频消融术在心脏瓣膜病并发心房颤动患者中的临床应用对比观察[J]. 山东医药, 2021, 61(27): 74-76.
[6] 王斌, 蔡薛芳, 林乐清. 重组人脑利钠肽联合左西孟旦治疗脓毒症心力衰竭的效果观察[J]. 中华全科医学, 2022, 20(3): 379-383.
[7] 武敏, 张鑫, 司婧媛, 等. 沙库巴曲缬沙坦在中青年男性高血压性心脏病心力衰竭患者中短期疗效[J]. 临床军医杂志, 2022, 50(10): 1034-1038.
[8] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 慢性心力衰竭基层诊疗指南 (实践版·2019)[J]. 中华全科医师杂志, 2019, 18(10): 948-956.
[9] 李屏. 瓣膜性心脏病心力衰竭治疗指南[C]//贵州省医学会心血管病学分会、贵州省医学会心电生理与起搏分会. 贵州省医学会心血管病学分会、贵州省医学会心电生理与起搏分会2008年学术年会专题讲座及论文摘要汇编, 2008: 3-4.
[10] 中国医师协会心力衰竭专业委员会, 国家心血管病专家委员会心力衰竭专业委员会, 中华心力衰竭和心肌病杂志编辑委员会. 中国心力衰竭患者离子管理专家共识[J]. 中华心力衰竭和心肌病杂志, 2020, 4(1): 16-31.
[11] 谭本超. 小剂量沙库巴曲缬沙坦钠片治疗高龄慢性射血分数减低型心力衰竭的临床研究[J]. 中西医结合心脑血管病杂志, 2022, 20(15): 2795-2797.
[12] 王其琼, 赵紫楠, 李少强, 等. 沙库巴曲缬沙坦治疗心力衰竭的快速卫生技术评估[J]. 中国新药杂志, 2022, 31(5): 491-499.
[13] 刘丽芬, 郭婷婷, 付悦, 等. 沙库巴曲缬沙坦治疗慢性心力衰竭合并肺动脉高压的临床疗效分析[J]. 中国药物与临床, 2021, 21(14): 211-213.
[14] 肖文丽, 张莹, 高铸烨, 等. 左西孟旦联合重组人脑利钠肽治疗急性心力衰竭疗效和安全性的Meta分析[J]. 中西医结合心脑血管病杂志, 2021, 19(11): 1795-1801.
[15] 李锦爽, 戚冉冉, 王万虹, 等. 沙库巴曲缬沙坦钠对急性前壁心肌梗死合并急性心功能不全患者短期预后的影响[J]. 中国药房, 2021, 32(23): 232-236.
[16] 王宏娟, 陶启乐. 沙库巴曲缬沙坦联合美托洛尔对老年慢性心力衰竭患者心功能, 血管内皮功能及神经内分泌因子的影响[J]. 中国老年学杂志, 2021, 41(23): 511-515.
[17] LEI Q, YU Z, LI H, et al.Fatty acid-binding protein 5 aggravates pulmonary artery fibrosis in pulmonary hypertension secondary to left heart disease via activating wnt/β-catenin pathway[J]. J Adv Res, 2022, 40(11): 197-206.
[18] ELKHOLI IE, ELSHERBINY ME, EMARA M.Myoglobin: From physiological roles to potential implications in cancer[J]. Biochim Biophys Acta Rev Cancer, 2022, 17(3): 188-196.
[19] LIU Y, MU Y, LI Z, et al.Extracellular matrix metalloproteinase inducer in brain ischemia and intracerebral hemorrhage[J]. Front Immunol, 2022, 31(13): 986-999.
[20] 郭丽芬, 胡晓军, 程丽丹, 等. 沙库巴曲缬沙坦钠片对慢性心力衰竭病人血清炎性因子及心肌损伤标志物的影响[J]. 中西医结合心脑血管病杂志, 2021, 19(16): 423-426.